{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:24:55Z","timestamp":1784431495221,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.mehy.2020.110112","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T22:07:25Z","timestamp":1594850845000},"page":"110112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)"],"prefix":"10.1016","volume":"143","author":[{"given":"Flavio A.","family":"Cadegiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Goren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Wambier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110112_b0005","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published online ahead of print, 2020 Mar 11] [published correction appears in Lancet. 2020 Mar 12;:]. Lancet. 2020;S0140-6736(20)30566-3."},{"key":"10.1016\/j.mehy.2020.110112_b0010","doi-asserted-by":"crossref","unstructured":"Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application [published online ahead of print, 2020 Mar 10]. Ann Intern Med. 2020;10.7326\/M20-0504.","DOI":"10.7326\/M20-0504"},{"key":"10.1016\/j.mehy.2020.110112_b0015","unstructured":"Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [published online ahead of print, 2020 Mar 13]. JAMA Intern Med. 2020;10.1001\/jamainternmed.2020.0994."},{"key":"10.1016\/j.mehy.2020.110112_b0020","doi-asserted-by":"crossref","unstructured":"Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease [published online ahead of print, 2020 Feb 28]. Chin Med J (Engl). 2020;10.1097\/CM9.0000000000000775.","DOI":"10.1097\/CM9.0000000000000775"},{"key":"10.1016\/j.mehy.2020.110112_b0025","doi-asserted-by":"crossref","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020 March 11 (Epub ahead of print).","DOI":"10.1016\/S2213-2600(20)30116-8"},{"key":"10.1016\/j.mehy.2020.110112_b0030","first-page":"28","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mehy.2020.110112_b0035","doi-asserted-by":"crossref","first-page":"E587","DOI":"10.1152\/ajpendo.00136.2020","article-title":"Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?","volume":"318","author":"Cadegiani","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.mehy.2020.110112_b0040","unstructured":"Wambier CG, Goren A. SARS-COV-2 infection is likely to be androgen mediated [published online ahead of print, 2020 Apr 10]. J Am Acad Dermatol. 2020;S0190-9622(20)30608-3."},{"key":"10.1016\/j.mehy.2020.110112_b0045","doi-asserted-by":"crossref","unstructured":"Goren A, McCoy J, Wambier CG, et al. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy [published online ahead of print, 2020 Apr 1]. Dermatol Ther. 2020;e13365.","DOI":"10.1111\/dth.13365"},{"key":"10.1016\/j.mehy.2020.110112_b0050","doi-asserted-by":"crossref","unstructured":"Goren A, Vano-Galvan S, Wambier CG, et al. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain \u2013 a potential clue to the role of androgens in COVID-19 severity [published online ahead of print, 2020 Apr 16]. J Cosmet Dermatol. 2020;10.1111\/jocd.13443.","DOI":"10.1111\/jocd.13443"},{"key":"10.1016\/j.mehy.2020.110112_b0055","doi-asserted-by":"crossref","unstructured":"Sommerstein R, Gr\u00e4ni C. Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19. BMJ 2020;368:m810-m810(https:\/\/www.bmj.com\/content\/368\/bmj.m810\/rr-2. opens in new tab).","DOI":"10.1136\/bmj.m810"},{"key":"10.1016\/j.mehy.2020.110112_b0060","doi-asserted-by":"crossref","unstructured":"Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens 2020March 11 (Epub ahead of print).","DOI":"10.1097\/HJH.0000000000002450"},{"key":"10.1016\/j.mehy.2020.110112_b0065","doi-asserted-by":"crossref","unstructured":"Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020 March 18 (Epub ahead of print).","DOI":"10.1093\/jtm\/taaa041"},{"key":"10.1016\/j.mehy.2020.110112_b0070","doi-asserted-by":"crossref","unstructured":"Guo X, Zhu Y, Hong Y. Decreased Mortality of COVID-19 with Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients with Hypertension:A Meta-Analysis [published online ahead of print, 2020 May 27]. Hypertension. 2020;10.1161\/HYPERTENSIONAHA.120.15572.","DOI":"10.1161\/HYPERTENSIONAHA.120.15572"},{"key":"10.1016\/j.mehy.2020.110112_b0075","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID- 19: A systematic review and meta-analysis [published online ahead of print, 2020 May 15]","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.mehy.2020.110112_b0080","doi-asserted-by":"crossref","unstructured":"Mackey K, King VJ, Gurley S, et al. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults [published online ahead of print, 2020 May 15]. Ann Intern Med. 2020;10.7326\/M20-1515.","DOI":"10.7326\/M20-1515"},{"key":"10.1016\/j.mehy.2020.110112_b0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.mehy.2020.110112_b0090","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1210\/en.2004-0443","article-title":"The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult leydig cells of the testis","volume":"145","author":"Douglas","year":"2004","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.mehy.2020.110112_b0095","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol."},{"issue":"5","key":"10.1016\/j.mehy.2020.110112_b0100","first-page":"e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Mary","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.mehy.2020.110112_b0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (angiotensin II) conversion to angiotensin-(1\u20137) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2020.110112_b0110","doi-asserted-by":"crossref","unstructured":"Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv. 2020 Jan 26;2020.01.26.919985.","DOI":"10.1101\/2020.01.26.919985"},{"issue":"3","key":"10.1016\/j.mehy.2020.110112_b0115","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1253\/circj.CJ-10-0045","article-title":"Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis","volume":"74","author":"Imai","year":"2010","journal-title":"Circ J."},{"issue":"8","key":"10.1016\/j.mehy.2020.110112_b0120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.mehy.2020.110112_b0125","unstructured":"Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV [published online ahead of print, 2020 Feb 17]. Biochem Biophys Res Commun. 2020;S0006-291X(20)30339-9."},{"key":"10.1016\/j.mehy.2020.110112_b0130","first-page":"1","article-title":"The novel coronavirus 2019 (2019-nCoV) uses the SARS coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry in target cells","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.mehy.2020.110112_b0135","doi-asserted-by":"crossref","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell MC, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury. Nature Med 2005; 11:875\u2013879.","DOI":"10.1038\/nm1267"},{"key":"10.1016\/j.mehy.2020.110112_b0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","article-title":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa","volume":"12","author":"Xu","year":"2020","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.mehy.2020.110112_b0145","unstructured":"Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis. EXCLI J. 2020;19:410\u2013417. Published 2020 Mar 18."},{"key":"10.1016\/j.mehy.2020.110112_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4594","article-title":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.mehy.2020.110112_b0155","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.mehy.2020.110112_b0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.mehy.2020.110112_b0165","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin Sci"},{"key":"10.1016\/j.mehy.2020.110112_b0170","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: Prevention of angiotensin ii-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"issue":"17","key":"10.1016\/j.mehy.2020.110112_b0175","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2020.110112_b0180","doi-asserted-by":"crossref","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020March 4 (Epub ahead of print).","DOI":"10.1002\/ddr.21656"},{"key":"10.1016\/j.mehy.2020.110112_b0185","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"issue":"10","key":"10.1016\/j.mehy.2020.110112_b0190","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.1601896","article-title":"Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection","volume":"198","author":"Channappanavar","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2020.110112_b0195","doi-asserted-by":"crossref","unstructured":"Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1). doi: 10.1038\/s41467-019-13940-6.","DOI":"10.1038\/s41467-019-13940-6"},{"issue":"7","key":"10.1016\/j.mehy.2020.110112_b0200","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","article-title":"Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms","volume":"11","author":"Baig","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.mehy.2020.110112_b0205","doi-asserted-by":"crossref","unstructured":"Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients [published online ahead of print, 2020 Feb 27]. J Med Virol. 2020;10.1002\/jmv.25728.","DOI":"10.1002\/jmv.25728"},{"issue":"6","key":"10.1016\/j.mehy.2020.110112_b0210","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/1570161115666170201113817","article-title":"Mineralocorticoid antagonists in ESRD: an overview of clinical trial evidence","volume":"15","author":"Georgianos","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"10.1016\/j.mehy.2020.110112_b0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1139\/bcb-2014-0110","article-title":"Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?","volume":"93","author":"Hermidorff","year":"2015","journal-title":"Biochem Cell Biol"},{"issue":"11","key":"10.1016\/j.mehy.2020.110112_b0220","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1291\/hypres.28.925","volume":"28","author":"Nakano","year":"2005","journal-title":"Hypertens Res"},{"issue":"6","key":"10.1016\/j.mehy.2020.110112_b0225","first-page":"97","article-title":"Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure","volume":"31","author":"Dieterich","year":"2005","journal-title":"Fiziol Cheloveka"},{"issue":"1\u20133","key":"10.1016\/j.mehy.2020.110112_b0230","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110112_b0235","first-page":"B4265","article-title":"The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone","volume":"58","author":"Schjoedt","year":"2011","journal-title":"Dan Med Bull"},{"issue":"1","key":"10.1016\/j.mehy.2020.110112_b0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12079-018-0466-2","article-title":"Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression","volume":"13","author":"Kong","year":"2019","journal-title":"J Cell Commun Signal"},{"issue":"10","key":"10.1016\/j.mehy.2020.110112_b0245","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.amjhyper.2007.05.008","article-title":"Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats","volume":"20","author":"Takeda","year":"2007","journal-title":"Am J Hypertens."},{"issue":"4","key":"10.1016\/j.mehy.2020.110112_b0250","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/HJH.0b013e328325d861","article-title":"Effect of mineralocorticoid receptor blockade on the renal renin-angiotensin system in Dahl salt-sensitive hypertensive rats","volume":"27","author":"Zhu","year":"2009","journal-title":"J Hypertens"},{"issue":"9","key":"10.1016\/j.mehy.2020.110112_b0255","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000187500.24964.7A","article-title":"Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients","volume":"97","author":"Keidar","year":"2005","journal-title":"Circ Res."},{"issue":"6","key":"10.1016\/j.mehy.2020.110112_b0260","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ Res."},{"issue":"1","key":"10.1016\/j.mehy.2020.110112_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2162","article-title":"The emerging role of ACE2 in physiology and disease","volume":"212","author":"Hamming","year":"2007","journal-title":"J Pathol."},{"key":"10.1016\/j.mehy.2020.110112_b0270","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.mehy.2020.110112_b0275","doi-asserted-by":"crossref","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences","volume":"318","author":"South","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110112_b0280","first-page":"73","article-title":"Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism","volume":"57","author":"Sert","year":"2003","journal-title":"Acta Med Okayama"},{"issue":"4","key":"10.1016\/j.mehy.2020.110112_b0285","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0039-128X(69)80007-3","article-title":"Anti-androgenic activity of spironolactone","volume":"14","author":"Steelman","year":"1969","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.mehy.2020.110112_b0290","first-page":"35","article-title":"Antiandrogenic and antirenotropic effect of spironolactone","volume":"68","author":"Broulik","year":"1976","journal-title":"Endokrinologie"},{"issue":"4","key":"10.1016\/j.mehy.2020.110112_b0295","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ajh\/hpw003","article-title":"The role of aldosterone in obesity-related hypertension","volume":"29","author":"Kawarazaki","year":"2016","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.mehy.2020.110112_b0300","doi-asserted-by":"crossref","unstructured":"Pahlavani M, Kalupahana NS, Ramalingam L, Moustaid-Moussa N. Regulation and Functions of the Renin-Angiotensin System in White and Brown Adipose Tissue. Compr Physiol. 2017;7(4):1137-1150. Published 2017 Sep 12.","DOI":"10.1002\/j.2040-4603.2017.tb00776.x"},{"issue":"2","key":"10.1016\/j.mehy.2020.110112_b0305","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2010.391","article-title":"Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity","volume":"79","author":"Yvan-Charvet","year":"2011","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.mehy.2020.110112_b0310","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10409238.2012.694843","article-title":"The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms","volume":"47","author":"Kalupahana","year":"2012","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.mehy.2020.110112_b0315","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/HYPERTENSIONAHA.114.04912","article-title":"Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction","volume":"65","author":"Bender","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2020.110112_b0320","doi-asserted-by":"crossref","unstructured":"Vecchiola A, Fuentes CA, Solar I, et al. Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division. Front Endocrinol (Lausanne). 2020;11:223. Published 2020 Apr 21.","DOI":"10.3389\/fendo.2020.00223"},{"key":"10.1016\/j.mehy.2020.110112_b0325","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jsbmb.2013.02.012","article-title":"Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity","volume":"137","author":"Feraco","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"11","key":"10.1016\/j.mehy.2020.110112_b0330","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2217\/nnm-2016-0006","article-title":"Inflammatory monocyte\/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice","volume":"11","author":"Ji","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.mehy.2020.110112_b0335","doi-asserted-by":"crossref","unstructured":"Ji WJ, Ma YQ, Zhou X, et al. Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments. PLoS One. 2013;8(11):e81090. Published 2013 Nov 19. doi: 10.1371\/journal.pone.0081090.","DOI":"10.1371\/journal.pone.0081090"},{"issue":"7","key":"10.1016\/j.mehy.2020.110112_b0340","doi-asserted-by":"crossref","first-page":"R879","DOI":"10.1152\/ajpregu.00075.2014","article-title":"Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade","volume":"307","author":"Rafatian","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"8","key":"10.1016\/j.mehy.2020.110112_b0345","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/labinvest.2014.69","article-title":"The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis","volume":"94","author":"Zhang","year":"2014","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.mehy.2020.110112_b0350","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jss.2014.04.040","article-title":"Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor \u03baB, and inducible nitric oxide synthase","volume":"191","author":"Ozacmak","year":"2014","journal-title":"J Surg Res"},{"issue":"3","key":"10.1016\/j.mehy.2020.110112_b0355","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/08923973.2014.921690","article-title":"Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharide via inactivation of nuclear factor-\u03baB","volume":"36","author":"Kato","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1\u20133","key":"10.1016\/j.mehy.2020.110112_b0360","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejphar.2013.08.019","article-title":"Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models","volume":"718","author":"Lieber","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.mehy.2020.110112_b0365","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2020.110112_b0370","article-title":"Use of Spironolactone in SARS-CoV-2 ARDS Patients","volume":"30","author":"Yarta\u015f Dumanl\u0131","year":"2020","journal-title":"Turk J Anaesthesiol Reanim"},{"key":"10.1016\/j.mehy.2020.110112_b0375","doi-asserted-by":"crossref","unstructured":"Alifano M, Alifano P, Forgez P, et al. Renin-angiotensin system at the heart of COVID-19 pandemic. Biochimie. 2020;174:30. S030090842030078X.","DOI":"10.1016\/j.biochi.2020.04.008"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720321423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720321423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:29:11Z","timestamp":1759692551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720321423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":75,"alternative-id":["S0306987720321423"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110112","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110112"}}